Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Evommune

Status and phase: Enrolling; Phase 2

Conditions: Atoptic Dermatitis

Treatments: Drug: EVO756; Drug: Placebo control

Study type: Interventional

Funder types: Industry

Identifiers

NCT07150845

EVO756-AD001

Details and patient eligibility

About

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic AD that has been present for ≥6 months
• Validated-Investigator's Global Assessment score of ≥3
• EASI of ≥16
• BSA of AD involvement of ≥10%

Exclusion criteria

• Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
• Use of certain medications
• Presence of skin comorbidities or other condition(s) that may interfere with study assessments
• Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

120 participants in 4 patient groups, including a placebo group

Dose 1

Experimental group

Description:

Orally administered EVO756, Dose 1

Treatment:

Drug: EVO756

Drug: EVO756

Drug: EVO756

Dose 2

Experimental group

Description:

Orally administered EVO756, Dose 2

Treatment:

Drug: EVO756

Drug: EVO756

Drug: EVO756

Dose 3

Experimental group

Description:

Orally administered EVO756, Dose 3

Treatment:

Drug: EVO756

Drug: EVO756

Drug: EVO756

Placebo

Placebo Comparator group

Description:

Placebo control

Treatment:

Drug: Placebo control